Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript

Howard Robin: Okay. Since JZ is running that part of the organization, I will let him answer that. Go ahead, JZ.

Jonathan Zalevsky: Yes. So, through the years, we have been bringing in staff with expertise in both drug discovery and drug development in immunology indications. So, we have been actually bringing that in. And then when we have areas of either capability or another gap, then obviously we get help like others do from outside experts that help us reinforce some of our decision-making and thoughts. Besides that, collectively, within the team that’s been developing the pipeline, there are many, many years of experience in working in the immunology fields across multiple diseases, multiple kinds of immunology settings. And that’s across many companies and particularly in large pharma, where there was a lot of expertise there in the company. Thanks.

Unidentified Analyst: Thank you.

Operator: Thank you. And I am showing no further questions from our phone lines. I would now like to turn the conference back over to Howard Robin for any closing remarks.

Howard Robin: Great. Thank you everyone for joining us today. And again, I want to thank our employees for their commitment and focus through some of these difficult and challenging times, which we all seem to be having in biotech these days. We look forward to sharing our progress in the development of REZPEG with everybody, so please stay tuned. I think there is a lot of potential for this molecule. Thank you very much.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.